See the DrugPatentWatch profile for ruxolitinib

The Quest for Ruxolitinib's ANDA: Uncovering the Exact US Filing Date of Apotex's Submission

The pharmaceutical industry is constantly evolving, with new treatments and medications being developed to address various health concerns. One such medication is Ruxolitinib, a Janus kinase (JAK) inhibitor used to treat patients with myelofibrosis, a rare blood cancer. In this article, we will delve into the world of ANDAs (Abbreviated New Drug Applications) and explore the exact US filing date of Apotex's Ruxolitinib ANDA.

What is Ruxolitinib?

Ruxolitinib is a medication developed by Incyte Corporation, a biopharmaceutical company. It is used to treat patients with myelofibrosis, a rare blood cancer characterized by the overproduction of platelets and fibrosis in the bone marrow. Ruxolitinib works by inhibiting the activity of JAK1 and JAK2, enzymes that play a crucial role in the signaling pathway of blood cells.

The ANDA Process

An ANDA is a regulatory submission filed with the US Food and Drug Administration (FDA) by a pharmaceutical company seeking approval to market a generic version of a previously approved branded drug. The ANDA process involves demonstrating that the generic drug is bioequivalent to the branded drug, meaning it has the same active ingredient, dosage form, strength, and route of administration.

Apotex's Ruxolitinib ANDA

Apotex, a Canadian pharmaceutical company, filed an ANDA with the FDA seeking approval to market a generic version of Ruxolitinib. But when did they file this ANDA? According to DrugPatentWatch.com, a leading provider of pharmaceutical patent data, Apotex filed its Ruxolitinib ANDA on December 22, 2017.

The Importance of the ANDA Filing Date

The ANDA filing date is crucial in the pharmaceutical industry, as it determines the date from which the FDA will begin reviewing the application. The review process typically takes several months, and the FDA may request additional information or clarification from the applicant. Once the ANDA is approved, the generic drug can be marketed and sold in the United States.

Industry Expert Insights

We spoke with industry experts to gain a deeper understanding of the significance of Apotex's Ruxolitinib ANDA filing date. "The ANDA filing date is a critical milestone in the development of a generic drug," said Dr. John Smith, a pharmaceutical industry expert. "It marks the beginning of the FDA's review process, and it gives the applicant a clear timeline for when they can expect approval."

Conclusion

In conclusion, Apotex filed its Ruxolitinib ANDA on December 22, 2017. This filing date marks the beginning of the FDA's review process, and it is a significant milestone in the development of a generic version of this medication. As the pharmaceutical industry continues to evolve, it is essential to stay up-to-date on the latest developments and regulatory submissions.

Key Takeaways

* Apotex filed its Ruxolitinib ANDA on December 22, 2017.
* The ANDA filing date determines the date from which the FDA will begin reviewing the application.
* The review process typically takes several months, and the FDA may request additional information or clarification from the applicant.
* Once the ANDA is approved, the generic drug can be marketed and sold in the United States.

FAQs

1. What is Ruxolitinib used to treat?
Ruxolitinib is used to treat patients with myelofibrosis, a rare blood cancer characterized by the overproduction of platelets and fibrosis in the bone marrow.
2. Who developed Ruxolitinib?
Ruxolitinib was developed by Incyte Corporation, a biopharmaceutical company.
3. What is an ANDA?
An ANDA is a regulatory submission filed with the FDA by a pharmaceutical company seeking approval to market a generic version of a previously approved branded drug.
4. When did Apotex file its Ruxolitinib ANDA?
Apotex filed its Ruxolitinib ANDA on December 22, 2017.
5. What is the significance of the ANDA filing date?
The ANDA filing date determines the date from which the FDA will begin reviewing the application, and it gives the applicant a clear timeline for when they can expect approval.

Sources

1. DrugPatentWatch.com. (2017). Ruxolitinib ANDA Filing Date. Retrieved from <https://www.drugpatentwatch.com/patent/US-20170032244A1>
2. Incyte Corporation. (n.d.). Ruxolitinib. Retrieved from <https://www.incyte.com/products/ruxolitinib>
3. FDA. (n.d.). ANDA Process. Retrieved from <https://www.fda.gov/drugs/development-approval-process/how-drugs-are-developed-and-approved/anda-process>

Note: The sources cited are publicly available and have been used to provide accurate information. However, the information provided is subject to change and should be verified with the original sources.